title: Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms.
abstract: Constitutively activated signaling molecules are often the primary drivers of malignancy, and are favored targets for therapeutic intervention. However, the effectiveness of targeted inhibition of cell signaling can be blunted by compensatory signaling which generates adaptive resistance mechanisms and reduces therapeutic responses. Therefore, it is important to identify and target these compensatory pathways with combinations of targeted agents to achieve durable clinical benefit. In this report, we demonstrate the use of high-throughput combinatorial drug screening as a discovery tool to identify compensatory pathways that generate resistance to the cytotoxic effects of targeted therapy. We screened 420 drug combinations in 14 different cell lines representing three cancer lineages, and assessed the ability of each combination to cause synergistic cytotoxicity. Drug substitution studies were used to validate the functionally important drug targets. Of the 84 combinations that caused robust synergy in multiple cell lines, none were synergistic in more than half of the lines tested, and we observed no pattern of lineage specificity in the observed synergies. This reflects the plasticity of cell signaling networks, even among cell lines of the same tissue of origin. Mechanistic analysis of one novel synergistic combination identified in the screen, the multi-kinase inhibitor Ro31-8220 and lapatinib, demonstrated compensatory crosstalk between the p70S6 kinase and EGF receptor pathways. In addition, we identified BAD as a node of convergence between these two pathways that may be playing a role in the enhanced apoptosis observed upon combination treatment.
authors.affiliation: Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, USA.
authors.forename: Mark
authors.initials: M
authors.lastname: Axelrod
authors.forename: Vicki L
authors.initials: VL
authors.lastname: Gordon
authors.forename: Mark
authors.initials: M
authors.lastname: Conaway
authors.forename: Adel
authors.initials: A
authors.lastname: Tarcsafalvi
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Neitzke
authors.forename: Daniel
authors.initials: D
authors.lastname: Gioeli
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Weber
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm / Q000502:physiology; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D004357:Drug Synergism; D005434:Flow Cytometry; D057166:High-Throughput Screening Assays; D006801:Humans; D047468:Immunoprecipitation; D009369:Neoplasms / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents